AOU Città della Salute e della Scienza di Torino – PO Molinette

Protocolli di Ricerca Clinica in ambito oncologico:

Disordini linfoproliferativi AOU CDSS

Divisione Universitaria di Ematologia (Prof. Benedetto Bruno)

Divisione Ospedaliera di Ematologia (Dott. Freilone Roberto)

Titolo:	R1979-onc-2105 olympia 3 "a phase 3, open label, randomized study comparing the efficacy and safety of odronextamab (regn1979), an anti-cd20 × anti-cd3 bispecific antibody, in combination with chop (odro-chop) versus rituximab in combination with chop (r-chop) in previously untreated participants with diffuse large b-cell lymphoma (dlbcl)"
Patologia:	Diffuse large b-cell lymphoma (dlbcl), diagnosi
Tipo di Studio:	interventistico, randomizzato
Fase:	III
Principali criteri di inclusione:	• Previously untreated participants for lymphoma CD20+ • Have measurable disease with at least one nodal lesion with LDi greater than 1.5 cm or at least one extranodal lesion with LDi greater than 1.0 cm • ECOG $\leq$ 2. • IPI $\geq$2 • Adequate hematologic and organ function
Principali criteri di esclusione:	• Central nervous system (CNS) involvement with lymphoma • History of or current relevant CNS pathology • Peripheral neuropathy Grade ≥3 • Prior organ transplantation
Sede e contatti	torino, molinette divisione universitaria di ematologia pi: prof.ssa federica cavallo (f.cavallo@unito.it) study coordinator: irene scavini (irene.scavini@unito.it)